Federal
A resolution designating February 28, 2021, as "Rare Disease Day".
Source: Congress.gov ·
788 words in original text
Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
III
117TH CONGRESS
1ST SESSION
S. RES. 74
Designating February 28, 2021, as ‘‘Rare Disease Day’’.
IN THE SENATE OF THE UNITED STATES
FEBRUARY 24, 2021
Mr. BROWN (for himself, Mr. BARRASSO, Mr. BLUMENTHAL, Mr. SCOTT of
South Carolina, Ms. KLOBUCHAR, Mr. WICKER, Mr. MARKEY, and Mr.
BOOKER) submitted the following resolution; which was considered and
agreed to
RESOLUTION
Designating February 28, 2021, as ‘‘Rare Disease Day’’.
Whereas a rare disease or disorder is a disease or disorder
that affects a small number of patients;
Whereas, in the United States, a rare disease or disorder
typically affects fewer than 200,000 individuals;
Whereas, as of the date of the adoption of this resolution,
more than 7,000 rare diseases or disorders affect ap-
proximately 1 in 10 individuals in the United States;
Whereas children with rare diseases or disorders account for
a significant portion of the population affected by rare
diseases or disorders in the United States;
Whereas many rare diseases and disorders are serious and
life-threatening and lack effective treatments;
VerDate Sep 11 2014
23:36 Feb 24, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\SR74.ATS
SR74
pamtmann on DSKBC07HB2PROD with BILLS
2
•SRES 74 ATS
Whereas, as a result of the enactment of the Orphan Drug
Act (Public Law 97–414; 96 Stat. 2049), important ad-
vances have been made in the research and treatment of
rare diseases and disorders;
Whereas the Food and Drug Administration has made strides
in gathering patient perspectives to inform the drug re-
view process as part of the Patient-Focused Drug Devel-
opment program, an initiative that was reaffirmed under
the FDA Reauthorization Act of 2017 (Public Law 115–
52; 131 Stat. 1005);
Whereas, although the Food and Drug Administration has
approved more than 880 orphan indications for drugs
and biological products for the treatment of rare diseases
and disorders, 90 percent of individuals in the United
States with a rare disease or disorder are not receiving
an FDA-approved treatment for their condition;
Whereas limited treatment options and difficulty obtaining
reimbursement for life-altering and lifesaving treatments
can be challenging for individuals with rare diseases or
disorders and their families;
Whereas rare diseases and disorders include sickle cell ane-
mia, spinal muscular atrophy, common variable immune
deficiency, median arcuate ligament syndrome, glycogen
storage disease type V, pulmonary hypertension, hemo-
philia, cystic fibrosis, sarcoidosis, amyotrophic lateral
sclerosis, and autosomal recessive polycystic kidney dis-
ease;
Whereas individuals with rare diseases or disorders can expe-
rience difficulty in obtaining accurate diagnoses and find-
ing physicians or treatment centers with expertise in
their rare disease or disorder;
VerDate Sep 11 2014
23:36 Feb 24, 2021
Jkt 019200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\SR74.ATS
SR74
pamtmann on DSKBC07HB2PROD with BILLS
3
•SRES 74 ATS
Whereas the 116th Congress passed a 4-year extension of the
Rare Pediatric Disease Priority Review Voucher program
under section 529(b) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 360ff(b)) as part of the Consoli-
dated Appropriations Act, 2021 (Public Law 116–260;
134 Stat. 1182), providing an incentive for the develop-
ment of therapies for children with rare diseases;
Whereas the 116th Congress passed the Advancing Care for
Exceptional Kids Act (Public Law 116–16; 133 Stat.
852), improving access to coordinated, patient-centered
health care for children with complex and rare medical
conditions in Medicaid;
Whereas the Food and Drug Administration and the National
Institutes of Health support research on the treatment of
rare diseases and disorders;
Whereas 2021 marks the 38th anniversary of the enactment
of the Orphan Drug Act (Public Law 97–414; 96 Stat.
2049);
Whereas Rare Disease Day is observed each year on the last
day of February;
Whereas Rare Disease Day is a global event that was first
observed in the United States on February 28, 2009, and
was observed in more than 100 countries in 2020; and
Whereas Rare Disease Day is expected to be observed glob-
ally for years to come, providing hope and information
for rare disease and disorder patients around the world:
Now, therefore, be it
Resolved, That the Senate—
1
(1) designates February 28, 2021, as ‘‘Rare
2
Disease Day’’; and
3
VerDate Sep 11 2014
23:36 Feb 24, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\SR74.ATS
SR74
pamtmann on DSKBC07HB2PROD with BILLS
4
•SRES 74 ATS
(2) recognizes the importance of, with respect
1
to rare diseases and disorders—
2
(A) improving awareness;
3
(B) encouraging accurate and early diag-
4
nosis; and
5
(C) supporting national and global efforts
6
to develop effective treatments, diagnostics, and
7
cures.
8
Æ
VerDate Sep 11 2014
23:36 Feb 24, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\SR74.ATS
SR74
pamtmann on DSKBC07HB2PROD with BILLS
Important: This plain English summary was generated by AI and is provided for informational purposes only.
It is not legal advice. Always consult the official bill text on Congress.gov
or a qualified attorney for legal matters.